Imatinib induces demethylation of miR-203 gene: An epigenetic mechanism of anti-tumor effect of imatinib

Leukemia Research

Volumn 37, Issue 10, 2013, Pages 1278-1286

  Shibuta, Tatsuki ^a   Honda, Emi ^b   Shiotsu, Hiromichi ^a   Tanaka, Yuka ^a   Vellasamy, Shalini ^c   Shiratsuchi, Motoaki ^b   Umemura, Tsukuru ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

CML; DNA methyltransferase; Methylation; MicroRNA; MiR 203

Indexed keywords

ABELSON KINASE; ABL1 PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; IMATINIB; UNCLASSIFIED DRUG;

ABL1 GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BCR GENE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE INTERACTION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MICROARRAY ANALYSIS; MICRORNA 203 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA GENE; TUMOR SUPPRESSOR GENE; UPREGULATION;

CML; DNA METHYLTRANSFERASE; METHYLATION; MICRORNA; MIR-203;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICRORNAS; PIPERAZINES; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RNA, MESSENGER;

EID: 84883561421     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.019     Document Type: Article

References (37)

1. Branford S. Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematol Am Soc Hematol Educ Program 2007, 37:6-83.
2. Florean C., Schnekenburger M., Grandjenette C., Dicato M., Diederich M. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 2011, 3(5):581-609.
3. Wolffe A.P., Matzke M.A. Epigenetics: regulation through repression. Science 1999, 286(5439):481-486.
4. San José-Eneriz E., Agirre X., Jiménez-Velasco A., Cordeu L., Martín V., Arqueros V., et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer 2009, 45(10):1877-1889.
5. Kusy S., Cividin M., Sorel N., Brizard F., Guilhot F., Brizard A., et al. p14ARF, p15INK4b, and p16INK4a methylation status in chronic myelogenous leukemia. Blood 2003, 101(1):374-375.
6. Yang H., Liang H., Yan J.S., Tao R., Hao S.G., Ma L.Y. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia. Int J Hematol 2012, 96(1):65-73.
7. Wu S.C., Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 2010, 11(9):607-620.
8. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010, 11(9):597-610.
9. Suzuki H.I., Miyazono K. Emerging complexity of microRNA generation cascades. J Biochem 2011, 149(1):15-25.
10. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
11. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269.
12. Osada H., Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007, 28(1):2-12.
13. Fabbri M., Garzon R., Andreeff M., Kantarjian H.M., Garcia-Manero G., Calin G.A. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 2008, 22(6):1095-1105.
14. Kong Y.W., Ferland-McCollough D., Jackson T.J., Bushell M. MicroRNAs in cancer management. Lancet Oncol 2012, 13(6):e249-e258.
15. Kozaki K., Inazawa J. Tumor-suppressive microRNA silenced by tumor-specific DNA hypermethylation in cancer cells. Cancer Sci 2012, 103(5):837-845.
16. Bueno M.J., Pérez de Castro I., Gómez de Cedrón M., Santos J., Calin G.A., Cigudosa J.C., et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008, 13(6):496-506.
17. Agirre X., Vilas-Zornoza A., Jiménez-Velasco A., Martin-Subero J.I., Cordeu L., Gárate L., et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009, 69(10):4443-4453.
18. Calin G.A., Cimmino A., Fabbri M., Ferracin M., Wojcik S.E., Shimizu M., et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008, 105(13):5166-5171.
19. Rokah O.H., Granot G., Ovcharenko A., Modai S., Pasmanik-Chor M., Toren A., et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS ONE 2012, 7(4):e35501.
20. Pelosi E., Labbaye C., Testa U. MicroRNAs in normal and malignant myelopoiesis. Leuk Res 2009, 33(12):1584-1593.
21. Scholl V., Hassan R., Zalcberg I.R. miRNA-451: a putative predictor marker of imatinib therapy response in chronic myeloid leukemia. Leuk Res 2012, 36(1):119-121.
22. Radujkovic A., Schad M., Topaly J., Veldwijk M.R., Laufs S., Schultheis B.S., et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL- inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005, 19(7):1198-1206.
23. Kasper B., Fruehauf S., Schiedlmeier B., Buchdunger E., Ho A.D., Zeller W.J. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor: activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother Pharmacol 1999, 44(5):433-438.
24. Suzuki H.I., Arase M., Matsuyama H., Choi Y.L., Ueno T., Mano H., et al. MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol Cell 2011, 44(3):424-436.
25. Wong K.Y., Yu L., Chim C.S. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics 2011, 3(1):83-92.
26. Chim C.S., Wong K.Y., Qi Y., Loong F., Lam W.L., Wong L.G., et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010, 31(4):745-750.
27. Heller G., Weinzierl M., Noll C., Babinsky V., Ziegler B., Altenberger C., et al. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res 2012, 18(6):1619-1629.
28. Gao X.N., Lin J., Li Y.H., Gao L., Wang X.R., Wang W., et al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 2011, 30(31):3416-3428.
29. Kozaki K., Imoto I., Mogi S., Omura K., Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008, 68(7):2094-2105.
30. Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I., Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31(5):766-776.
31. Wong K.Y., Liang R., So C.C., Jin D.Y., Costello J.F., Chim C.S. Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol 2011, 154(5):569-578.
32. Craig V.J., Cogliatti S.B., Rehrauer H., Wündisch T., Müller A. Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives helicobacter-associated gastric lymphomagenesis. Cancer Res 2011, 71(10):3616-3624.
33. Agirre X., Jiménez-Velasco A., San José-Enériz E., Garate L., Bandrés E., Cordeu L., et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res 2008, 6(12):1830-1840.
34. Mizuno S., Chijiwa T., Okamura T., Akashi K., Fukumaki Y., Niho Y., et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001, 97(5):1172-1179.
35. Nishioka C., Ikezoe T., Yang J., Udaka K., Yokoyama A Imatinib causes epigenetic alterations of PTEN gene via upregulation of DNA methyltransferases and polycomb group proteins. Blood Cancer J 2011, 1(12):e48.
36. Soriano A.O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110(7):2302-2308.
37. Raffoux E., Cras A., Recher C., Boëlle P.Y., de Labarthe A., Turlure P., et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010, 1(1):34-42.